Investor Presentaiton
Board of Directors
Clarity's board has extensive capital markets, radiopharmaceutical and broader life sciences experience
Dr Alan Taylor
Executive Chairman
Rosanne Robinson
Non-Executive Director
Dr Chris Roberts
Non-Executive Director
Dr Thomas Ramdahl
Non-Executive Director
Dr Gillies O'Bryan-Tear
Non-Executive Director
Mr Robert Thomas
Non-Executive Director
Dr Colin Biggin
Managing Director
Ms Robinson brings extensive
experience in the nuclear
field and a range of
commercial expertise to the
Company and has over 25
years of experience in both
governance and
management roles in public
and private companies and
government. Ms Robinson is
the General Manager of
Business Development at
Australian Nuclear Science
and Technology
Organisation. Ms Robinson's
in-depth knowledge of the
nuclear medicine industry
provides the Company with a
clear vision across the
dynamics of, and most recent
changes in, the sector.
Dr Roberts has over 40 years
of experience in the medical
innovation space and has
served on the boards of a
number of ASX-listed
companies during his career.
Dr Roberts was previously the
CEO of ASX-listed company
Cochlear Limited and
Chairman of ASX-listed
company Sirtex Medical Ltd.
Dr Roberts was also Executive
Vice-President and a director
of the dual-listed (ASX and
NYSE) company ResMed Inc.,
a global sleep disorder
treatment company. Dr
Roberts is Chairman of the
ASX-listed company Oncosil
Ltd.
Dr Ramdahl is a
pharmaceutical executive
with over 20 years of clinical
and development
experience. In 2001, he
became President and the
first CEO of Algeta ASA. When
Dr Ramdahl joined Algeta, he
was one of six employees and
he played an instrumental role
in its success, serving in several
senior positions within the
company through to and post
the acquisition of Algeta by
Bayer AG in 2014 for US$2.9
billion. Dr Ramdahl has
authored more than 40
publications and is a co-
inventor of several patents. Dr
Ramdahl serves as Chairman
of Precirix (Belgium) and
AppSens AS (Norway).
Dr O'Bryan-Tear has over 30
years of experience in the
pharmaceutical industry in
clinical development,
medical management and
commercial roles. He has held
senior leadership roles in large
and small pharmaceutical
and biotech companies in
the US and Europe and has
been involved in multiple
product approvals. He was
previously the Chief Medical
Officer of Algeta ASA. Dr
O'Bryan-Tear has been an
adviser to several US and
European biotech companies
and is a member of the
Scientific Advisory Board of
Fusion Pharmaceuticals Inc.
(Canada).
Mr Thomas has a strong
background in financial
services and capital markets
including advising on the IPOS
of the Commonwealth Bank
of Australia and Qantas. He is
the former CEO of County
NatWest Securities and of Citi
Corporate and Investment
Bank Australasia. Mr Thomas
has held the position of
Chairman at Australian
Wealth Management Ltd,
TAL, HeartWare® International
Inc, AusBio Ltd, Grahger Retail
Securities Pty Ltd and
Starpharma Holdings Ltd. He is
a non-executive director of
Biotron Limited and O'Connell
Street Associates.
CLARITY
2014 MEIE
32View entire presentation